- Home
- / X4 Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
X4 Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.5
2024-10-29
Market Capitalization
$83.9 M
2024-10-29
Revenue
$6.5 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.5M | 3.0M | 2.6M | 6.5M | ||||
| Cost of goods sold | 797.0K | 5.8M | ||||||
| Gross profit | 1.8M | 743.0K | ||||||
| Gross profit margin, % | 68.8% | 11.4% | ||||||
| General and administrative expense | 18.4M | 17.6M | 20.9M | 24.7M | 27.0M | 35.5M | 61.5M | 43.5M |
| Operating expense total | 49.4M | 47.8M | 62.9M | 75.3M | 88.1M | 38.2M | 87.6M | |
| EBIT | (45.9M) | (51.7M) | (59.9M) | (85.1M) | (87.6M) | (107.5M) | (36.4M) | (86.9M) |
| EBIT margin, % | -1311.0% | -1995.8% | -1423.6% | -1336.7% | ||||
| Interest income | 809.0K | 1.2M | 273.0K | 10.0K | 219.0K | 4.6M | 5.8M | 4.6M |
| Interest expense | 1.0M | 2.1M | 2.7M | 3.6M | 4.0M | 5.8M | 7.8M | |
| Pre tax profit | (43.0M) | (52.8M) | (62.0M) | (88.7M) | (93.8M) | (101.1M) | (37.1M) | (79.2M) |
| Income tax expense | 148.0K | 17.0K | 28.0K | 78.0K | 310.0K | 41.0K | ||
| Net Income | (43.0M) | (52.8M) | (62.1M) | (88.7M) | (93.9M) | (101.2M) | (37.4M) | |
| EPS | (1.5) | (0.2) | (1.9) |